Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • USFDA issues warning...

    USFDA issues warning letter to Megafine Pharma for Vapi plant

    Written by supriya kashyap kashyap Published On 2017-03-10T12:47:51+05:30  |  Updated On 10 March 2017 12:47 PM IST
    USFDA issues warning letter to Megafine Pharma for Vapi plant

    New Delhi : The US health regulator has issued a warning letter to Mumbai-based Megafine Pharma for violations of good manufacturing norms at its Vapi facility in Gujarat.


    Summarising significant deviations from CGMP (current good manufacturing practice) norms at the Vapi unit, the US Food and Drug Administration (USFDA) said that its investigators observed several lapses.


    In the letter to the company's Business Development Director Shailesh Sanghvi, USFDA said, "Our investigators found that you sourced material from a facility on FDA Import Alert 66-40 for failure to meet CGMP requirements."


    The plant manufactures active pharmaceutical ingredient (API) intermediates. The firm's quality unit approved the use of adulterated materials to manufacture drugs, it added.


    The FDA termed the response of the company as inadequate.


    The other issue flagged by the regulator was "failure to establish and follow adequate written procedures for cleaning equipment and its release for use in API manufacture, and to maintain adequate records of major equipment usage."


    Response by the company failed to address the adequacy of preventive maintenance to ensure that the equipment is in a good state of repair and will not contaminate drugs with material accumulated on surfaces that come in contact with its drugs, FDA said.


    The USFDA further said that "your test methods were not capable of demonstrating the purity of your drugs."


    Another major violation of CGMP norms was that the company's quality system did not adequately ensure the accuracy and integrity of data to support the safety, effectiveness and quality of the drugs it manufactures, FDA said.


    "Until you correct all deviations completely and we confirm your compliance with CGMP, FDA may withhold approval of any new applications or supplements listing your firm as a drug manufacturer," the letter said.


    Failure to correct these violations may also result in the USFDA continuing to refuse admission of articles manufactured at Megafine Pharma's Vapi plant, it added.

    Active Pharmaceutical IngredientcGMPMegafine PharmaShailesh SanghviUS Food and Drug AdministrationUSFDAVapi plantwarning letter
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok